

ASX RELEASE

19 December 2024

Results of Extraordinary General Meeting

Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to confirm that each of the resolutions put to its Extraordinary General Meeting held earlier today were <u>carried</u>.

Details of the results of the meeting are attached.

This ASX announcement is authorised for release by the Company Secretary.

- End -

Investor Contact: Dr Chris Burns Chief Executive Officer <u>chris@ampliatx.com</u> Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit <u>www.ampliatx.com</u> and follow Amplia on <u>Twitter</u> (@ampliatx), <u>Threads</u> (@ampliatx) and <u>LinkedIn</u>.

AMPLIA THERAPEUTICS LIMITED

Extraordinary General Meeting Thursday, 19 December 2024 Results of Meeting



The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution
	Result								
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Ratification of Placement Shares	Ordinary	125,751,824	830,879	3,072,494	26,441,848	128,824,318	830,879	26,441,848	Carried
		96.99%	0.64%	2.37%		99.36%	0.64%		
2 Issue of Attaching Options under the Placement	Ordinary	125,521,809	1,043,994	3,089,394	26,441,848	128,611,203	1,043,994	26,441,848	Carried
		96.81%	0.81%	2.38%		99.19%	0.81%		
3 Issue of Lead Manager Options	Ordinary	152,875,378	2,499,494	3,072,869	108,420	155,948,247	2,499,494	108,420	Carried
		96.48%	1.58%	1.94%		98.42%	1.58%		
4 Issue of Sub-Underwriter Options	Ordinary	150,874,436	2,527,914	3,322,494	171,150	154,196,930	2,527,914	171,150	Carried
		96.27%	1.61%	2.12%		98.39%	1.61%		
5 Issue PLC Shares and Opt to Dr Warwick Tong	Ordinary	151,727,535	672,900	3,072,494	3,083,232	154,800,029	672,900	3,083,232	Carried
		97.59%	0.43%	1.98%		99.57%	0.43%		
6 Issue PLC Shares and Opt to Dr Christopher Burns	Ordinary	150,907,487	616,900	3,187,998	3,843,776	154,095,485	616,900	3,843,776	Carried
		97.54%	0.40%	2.06%		99.60%	0.40%		
7 Issue PLC Shares and Opt to Dr Robert Peach	Ordinary	149,687,245	1,337,404	3,072,494	4,459,018	152,759,739	1,337,404	4,459,018	Carried
		97.14%	0.87%	1.99%		99.13%	0.87%		
8 Issue PLC Shares and Opt to Ms Jane Bell	Ordinary	151,243,614	1,308,984	3,072,494	95,405	154,316,108	1,308,984	95,405	Carried
		97.18%	0.84%	1.97%		99.16%	0.84%		

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.